Consensus NRx Pharmaceuticals, Inc.

Equities

BRPA

US6294442099

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-11 pm EDT			5-day change	1st Jan Change
3.32 ^USD	+4.40%		-6.21%	-27.83%

Jun. 03	Certain Warrant of NRx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 3-JUN-2024.	CI
Jun. 03	Certain Common Stock of NRx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 3-JUN-2024.	CI

Evolution of the average Target Price on NRx Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

6557800a2005e7e09029c9aa92ec502.HtrMUKxN2ubpNs4hxwSS9FlJNYI23qhxf_PFwG6BlbA.e77haMMatI2TRJ1ln2KitiEBfPoHqZAiEayOgiruwsh8sJYe9AnplN96iw~cb9638538e4c332610e62816764b85ce

Analyst Recommendations on NRx Pharmaceuticals, Inc.

Ascendiant Capital Starts NRX Pharmaceuticals at Buy With $4 Price Target	22-11-09	MT
HC Wainwright Starts NRX Pharmaceuticals at Buy With $2 Price Target	22-06-30	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.32 USD

Average target price

31.5 USD

Spread / Average Target

+848.80%

High Price Target

43 USD

Spread / Highest target

+1,195.18%

Low Price Target

20 USD

Spread / Lowest Target

+502.41%

Consensus detail

Consensus revision (last 18 months)

Analysts covering NRx Pharmaceuticals, Inc.

Ascendiant Capital
HC Wainwright

Quarterly revenue - Rate of surprise

Company calendar